P Hemachandra Reddy

List of Publications by Year
in descending order

222	27,610	4372	5959
papers	citations	85 h-index	158 g-index

239	239	239	24528
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cell culture research in aging and Alzheimer's disease: The strategic use/reuse of untreated controls and savings people's tax dollars. Journal of Alzheimer's Disease Reports, 2025, 9, .	2.6	1
2	Gender differences in cognitive impairment among the elderly in rural West Texas counties. Journal of Alzheimer's Disease, 2025, 103, 687-705.	2.7	1
3	Mitochondria in Aging and Alzheimerâ€™s Disease: Focus on Mitophagy. Neuroscientist, 2024, 30, 440-457.	4.8	32
4	Alzheimer's disease and Alzheimerâ€™s disease-related dementias in Hispanics: Identifying influential factors and supporting caregivers. Ageing Research Reviews, 2024, 93, 102178.	12.1	20
5	A Combinational Therapy for Preventing and Delaying the Onset of Alzheimerâ€™s Disease: A Focus on Probiotic and Vitamin Co-Supplementation. Antioxidants, 2024, 13, 202.	5.8	20
6	Mechanisms of pain in aging and age-related conditions: Focus on caregivers. Ageing Research Reviews, 2024, 95, 102249.	12.1	6
7	Overlooked cases of mild cognitive impairment: Implications to early Alzheimerâ€™s disease. Ageing Research Reviews, 2024, 98, 102335.	12.1	45
8	Unraveling the NRF2 confusion: Distinguishing nuclear respiratory factor 2 from nuclear erythroid factor 2. Ageing Research Reviews, 2024, 98, 102353.	12.1	10
9	Effects of sleep deprivation on brain atrophy in individuals with mild cognitive impairment and Alzheimer's disease. Ageing Research Reviews, 2024, 99, 102397.	12.1	11
10	Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements. Ageing Research Reviews, 2024, 99, 102410.	12.1	34
11	Unraveling the complexity of human brain: Structure, function in healthy and disease states. Ageing Research Reviews, 2024, 100, 102414.	12.1	45
12	Harnessing Artificial Intelligence for the Detection and Management of Colorectal Cancer Treatment. Cancer Prevention Research, 2024, 17, 499-515.	1.1	1
13	Acetylation of Steroidogenic Acute Regulatory Protein Sensitizes 17Î²-Estradiol Regulation in Hormone-Sensitive Breast Cancer Cells. International Journal of Molecular Sciences, 2024, 25, 8732.	4.5	0
14	Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimerâ€™s disease in elderly. Ageing Research Reviews, 2024, 100, 102457.	12.1	45
15	Serotonin in depression and Alzheimerâ€™s disease: Focus on SSRIâ€™s beneficial effects. Ageing Research Reviews, 2024, 101, 102537.	12.1	18
16	Expression and Function of StAR in Cancerous and Non-Cancerous Human and Mouse Breast Tissues: New Insights into Diagnosis and Treatment of Hormone-Sensitive Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 758.	4.5	11
17	Caregivers with Cancer Patients: Focus on Hispanics. Cancers, 2023, 15, 626.	4.1	20
18	Structural and physiological changes of the kidney with age and its impact on chronic conditions and COVID-19. Ageing Research Reviews, 2023, 88, 101932.	12.1	17

#	Article	IF	Citations
19	Current Status of Obesity: Protective Role of Catechins. Antioxidants, 2023, 12, 474.	5.8	31
20	Support Provided by Caregivers for Community-Dwelling Diabetic Hispanic Adults with Intellectual Disabilities and Comorbid Conditions. International Journal of Molecular Sciences, 2023, 24, 3848.	4.5	5
21	Alzheimerâ€™s Disease and Alzheimerâ€™s Disease-Related Dementias in African Americans: Focus on Caregivers. Healthcare (Switzerland), 2023, 11, 868.	2.5	10
22	Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies. Biomedicines, 2023, 11, 1126.	3.6	39
23	Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. World Journal of Gastroenterology, 2023, 29, 2064-2077.	4.7	5
24	Support Provided by Caregivers for Community-Dwelling Obesity Individuals: Focus on Elderly and Hispanics. Healthcare (Switzerland), 2023, 11, 1442.	2.5	4
25	Rlip Reduction Induces Oxidative Stress and Mitochondrial Dysfunction in Mutant Tau-Expressed Immortalized Hippocampal Neurons: Mechanistic Insights. Cells, 2023, 12, 1646.	4.8	8
26	Urgent needs of caregiving in ageing populations with Alzheimerâ€™s disease and other chronic conditions: Support our loved ones. Ageing Research Reviews, 2023, 90, 102001.	12.1	51
27	Healthy brain aging and delayed dementia in Texas rural elderly. Ageing Research Reviews, 2023, 91, 102047.	12.1	15
28	Alzheimerâ€™s disease and its related dementias in US Native Americans: A major public health concern. Ageing Research Reviews, 2023, 90, 102027.	12.1	21
29	Role of diet and exercise in aging, Alzheimerâ€™s disease, and other chronic diseases. Ageing Research Reviews, 2023, 91, 102091.	12.1	61
30	Epigenetic Dysregulation and Its Correlation with the Steroidogenic Machinery Impacting Breast Pathogenesis: Data Mining and Molecular Insights into Therapeutics. International Journal of Molecular Sciences, 2023, 24, 16488.	4.5	1
31	Epigenetic Dysregulation and Its Correlation with the Steroidogenic Machinery Impacting Breast Pathogenesis: Data Mining and Molecular Insights into Therapeutics. International Journal of Molecular Sciences, 2023, 24, 16488.	4.5	3
32	Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimerâ€™s disease. Human Molecular Genetics, 2022, 31, 1022-1034.	3.1	14
33	Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease. Human Molecular Genetics, 2022, 31, 423-439.	3.1	63
34	Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria. Ageing Research Reviews, 2022, 73, 101529.	12.1	123
35	A Novel Role for BRIP1/FANCJ in Neuronal Cells Health and in Resolving Oxidative Stress-Induced DNA Lesions. Journal of Alzheimer's Disease, 2022, 85, 207-221.	2.7	16
36	A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease. Human Molecular Genetics, 2022, 31, 1788-1805.	3.1	41

#	Article	IF	Citations
37	Rlip Depletion Alters Oncogene Transcription at Multiple Distinct Regulatory Levels. Cancers, 2022, 14, 527.	4.1	0
38	Early Cellular, Molecular, Morphological and Behavioral Changes in the Humanized Amyloid-Beta-Knock-In Mouse Model of Late-Onset Alzheimerâ€™s Disease. Cells, 2022, 11, 733.	4.8	22
39	Healthy Immunity on Preventive Medicine for Combating COVID-19. Nutrients, 2022, 14, 1004.	4.6	15
40	Protective Effects of Chaya against Mitochondrial and Synaptic Toxicities in the Type 2 Diabetes Mouse Model TallyHO. Cells, 2022, 11, 744.	4.8	4
41	Impact of Chronic Conditions and Dementia in Rural West Texas: A Healthy Aging Study. Journal of Alzheimer's Disease, 2022, 87, 33-49.	2.7	2
42	Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine, 2022, 184, 114-134.	2.8	474
43	Are mitophagy enhancers therapeutic targets for Alzheimerâ€™s disease?. Biomedicine and Pharmacotherapy, 2022, 149, 112918.	6.8	55
44	Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases. Biomedical Journal, 2022, 45, 733-748.	3.9	47
45	Behavioral Evidence for a Tau and HIV-gp120 Interaction. International Journal of Molecular Sciences, 2022, 23, 5514.	4.5	4
46	Rlip76: An Unexplored Player in Neurodegeneration and Alzheimerâ€™s Disease?. International Journal of Molecular Sciences, 2022, 23, 6098.	4.5	10
47	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. Biomedicines, 2022, 10, 1313.	3.6	25
48	A partial reduction of <scp>VDAC1</scp> enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model. Aging Cell, 2022, 21, .	7.0	31
49	Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 8561.	4.5	22
50	The Role of Obesity and Diabetes in Dementia. International Journal of Molecular Sciences, 2022, 23, 9267.	4.5	57
51	A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimerâ€™s Disease. Cells, 2022, 11, 2660.	4.8	30
52	Phosphorylated Tau in Alzheimerâ€™s Disease and Other Tauopathies. International Journal of Molecular Sciences, 2022, 23, 12841.	4.5	310
53	Amyloid Beta in Aging and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12924.	4.5	251
54	Therapeutics of Alzheimerâ€™s Disease: Recent Developments. Antioxidants, 2022, 11, 2402.	5.8	25

#	Article	IF	Citations
55	Improvement in Glycemic Control in Mice of Different Age Groups. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 519-527.	1.5	2
56	The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. Neuroscientist, 2021, 27, 331-339.	4.8	47
57	Synaptic basis of Alzheimerâ€™s disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Research Reviews, 2021, 65, 101208.	12.1	288
58	Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166014.	4.2	32
59	Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases. Frontiers in Aging Neuroscience, 2021, 12, .	4.1	89
60	Disparities in Breast Cancer Survivors in Rural West Texas. Cancer Control, 2021, 28, .	2.4	3
61	Age-Related Chronic Diseases and Alzheimerâ€™s Disease in Texas: A Hispanic Focused Study. Journal of Alzheimer's Disease Reports, 2021, 5, 121-133.	2.6	33
62	Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimerâ€™s disease. Human Molecular Genetics, 2021, 30, 847-864.	3.1	51
63	Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimerâ€™s disease. Human Molecular Genetics, 2021, 30, 789-810.	3.1	46
64	Anti-brain Aging Effects of Small Molecule Inhibitor DDQ. Molecular Neurobiology, 2021, , .	3.7	19
65	Sex Differences in Cardiovascular Disease and Cognitive Dysfunction in Rural West Elderly Texans. Journal of Alzheimer's Disease Reports, 2021, 5, 213-226.	2.6	5
66	Mitochondrial Dysfunctioning Induced by Hyperglycemia in the Liver Tissues of Diabetic Mice, TALLYHO/JngJ Strain and Ameliorative Action of a Small Peptide, SS31. Metabolism: Clinical and Experimental, 2021, 116, 154608.	5.5	2
67	Emerging role of nonâ€coding RNA in health and disease. Metabolic Brain Disease, 2021, 36, 1119-1134.	3.0	144
68	Elevated levels of MicroRNA-455-3p in the cerebrospinal fluid of Alzheimer's patients: A potential biomarker for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166052.	4.2	33
69	The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus. Cells, 2021, 10, 1340.	4.8	45
70	Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice. Mitochondrion, 2021, 58, 49-58.	4.2	25
71	Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic. Molecular Neurobiology, 2021, 58, 4694-4715.	3.7	58
72	Effects of Lipotoxicity in Brain Microvascular Endothelial Cells During Sirt3 Deficiency-Potential Role in Comorbid Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, .	4.1	21

#	Article	IF	Citations
73	Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Research Reviews, 2021, 68, 101338.	12.1	143
74	Protective effects of a small molecule inhibitor, DDQ against amyloid beta in Alzheimerâ€™s disease. Mitochondrion, 2021, 59, 17-29.	4.2	28
75	Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease. Human Molecular Genetics, 2021, 31, 244-261.	3.1	21
76	Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse. Free Radical Biology and Medicine, 2021, 172, 652-667.	2.8	145
77	Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166162.	4.2	27
78	Can healthy lifestyle reduce disease progression of Alzheimerâ€™s during a global pandemic of COVID-19?. Ageing Research Reviews, 2021, 70, 101406.	12.1	16
79	Mitochondrial Abnormalities and Synaptic Damage in Huntingtonâ€™s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics. Molecular Neurobiology, 2021, 58, 6350-6377.	3.7	51
80	Defective Autophagy and Mitophagy in Aging and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 14, .	3.0	123
81	Impaired mitochondrial bioenergetics and signaling pathways. , 2021, , 61-79.		1
82	The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimerâ€™s Disease. Cells, 2021, 10, 2790.	4.8	67
83	Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease. Pharmacological Research, 2021, 174, 105973.	9.1	68
84	MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: Relevance to Alzheimer's disease. Redox Biology, 2021, 48, 102182.	10.5	55
85	RALBP1 in Oxidative Stress and Mitochondrial Dysfunction in Alzheimerâ€™s Disease. Cells, 2021, 10, 3113.	4.8	17
86	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	3.6	20
87	COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. Cells, 2021, 10, 3291.	4.8	56
88	Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimerâ€™s disease. Human Molecular Genetics, 2020, 29, 49-69.	3.1	23
89	Current status of stem cell research: An editorial. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165635.	4.2	2
90	The role of synaptic microRNAs in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165937.	4.2	61

#	Article	IF	Citations
91	Defective mitophagy in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101191.	12.1	286
92	GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165974.	4.2	4
93	Gene expression of endocannabinoid system in HIV-1-related neuropathic pain model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165891.	4.2	3
94	Neural Underpinnings of Obesity: The Role of Oxidative Stress and Inflammation in the Brain. Antioxidants, 2020, 9, 1018.	5.8	46
95	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. Molecular Neurobiology, 2020, 57, 4856-4877.	3.7	31
96	Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. Journal of Alzheimer's Disease, 2020, 75, 353-383.	2.7	27
97	Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases. Cells, 2020, 9, 1345.	4.8	70
98	SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165889.	4.2	60
99	Gender differences in prevalence of myocardial infarction in rural West Texans. Zeitschrift Fur Gesundheitswissenschaften, 2020, , .	1.2	2
100	Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 11, .	4.1	119
101	Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice. Molecular Neurobiology, 2020, 58, 795-808.	3.7	32
102	Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2019, 72, S81-S93.	2.7	12
103	Dynamics of Dynamin-Related Protein 1 in Alzheimerâ€™s Disease and Other Neurodegenerative Diseases. Cells, 2019, 8, 961.	4.8	152
104	A New Discovery of MicroRNA-455-3p in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, S117-S130.	2.7	62
105	Potential role of E4orf1 protein in aging-associated impairment in glycemic control. Journal of Diabetes and Its Complications, 2019, 33, 261-265.	2.6	2
106	Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimerâ€™s Disease. Cells, 2019, 8, 488.	4.8	408
107	Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals?. Journal of Alzheimer's Disease, 2019, 72, S37-S58.	2.7	46
108	Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2428-2440.	4.2	85

#	Article	IF	Citations
109	Current Status of Healthy Aging and Dementia Research: A Symposium Summary. Journal of Alzheimer's Disease, 2019, 72, S11-S35.	2.7	6
110	Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2276-2284.	4.2	30
111	Amyloid Beta and MicroRNAs in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2019, 13, .	3.0	94
112	Molecular Basis of Alzheimerâ€™s Disease: Focus on Mitochondria. Journal of Alzheimer's Disease, 2019, 72, S95-S116.	2.7	100
113	Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimerâ€™s Disease. Cells, 2019, 8, 260.	4.8	67
114	Small molecules as therapeutic drugs for Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 96, 47-62.	2.3	134
115	Novel miRNA PC-5P-12969 in Ischemic Stroke. Molecular Neurobiology, 2019, 56, 6976-6985.	3.7	29
116	Current Issues in Chronic Diseases: A Focus on Dementia and Hypertension in Rural West Texans. Journal of Alzheimer's Disease, 2019, 72, S59-S69.	2.7	7
117	Lifestyle and Risk Factors of Dementia in Rural West Texas. Journal of Alzheimer's Disease, 2019, 72, S1-S10.	2.7	13
118	Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntingtonâ€™s Disease Progression. Journal of Alzheimer's Disease, 2019, 72, S177-S191.	2.7	12
119	Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2019, 72, S71-S79.	2.7	20
120	Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity. Human Molecular Genetics, 2019, 28, 177-199.	3.1	166
121	Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimerâ€™s disease. Drug Discovery Today, 2019, 24, 616-623.	7.7	50
122	Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimerâ€™s disease. Human Molecular Genetics, 2018, 27, 2502-2516.	3.1	259
123	Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1549-1565.	2.7	78
124	Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimerâ€™s disease. Human Molecular Genetics, 2018, 27, 1332-1342.	3.1	265
125	Protective Effects of Indian Spice Curcumin Against Amyloid-Î² in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 61, 843-866.	2.7	329
126	Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Human Molecular Genetics, 2018, 27, 2318-2329.	3.1	73

#	Article	IF	Citations
127	Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimerâ€™s disease. Human Molecular Genetics, 2018, 27, 30-40.	3.1	213
128	Liquid Crystals: A Novel Approach for Cancer Detection and Treatment. Cancers, 2018, 10, 462.	4.1	35
129	MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update. Frontiers in Aging Neuroscience, 2018, 10, .	4.1	124
130	Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1037-1045.	4.2	581
131	Methods needed to measure predictive accuracy: A study of diabetic patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1046-1053.	4.2	6
132	Dynamics of diabetes and obesity: Epidemiological perspective. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1026-1036.	4.2	217
133	Therapeutics of Neurotransmitters in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 1049-1069.	2.7	218
134	Editorial of the article. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1023-1025.	4.2	0
135	A Critical Assessment of Research on Neurotransmitters in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 969-974.	2.7	45
136	Mitochondria-Division Inhibitor 1 Protects Against Amyloid-Î² induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 147-162.	2.7	97
137	Maternal exercise upregulates mitochondrial gene expression and increases enzyme activity of fetal mouse hearts. Physiological Reports, 2017, 5, .	1.7	32
138	Aqua-soluble DDQ reduces the levels of Drp1 and AÎ² and inhibits abnormal interactions between AÎ² and Drp1 and protects Alzheimerâ€™s disease neurons from AÎ²- and Drp1-induced mitochondrial and synaptic toxicities. Human Molecular Genetics, 2017, 26, 3375-3395.	3.1	62
139	Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimerâ€™s disease. Human Molecular Genetics, 2017, 26, 1483-1496.	3.1	104
140	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities atÂSynapses of Alzheimerâ€™s disease Neurons. Journal of Alzheimer's Disease, 2017, 57, 975-999.	2.7	543
141	MicroRNA-455-3p as a potential peripheral biomarker for Alzheimerâ€™s disease. Human Molecular Genetics, 2017, 26, 3808-3822.	3.1	156
142	Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug Discovery Today, 2017, 22, 223-233.	7.7	39
143	Mitochondrial dysfunction and oxidative stress in metabolic disorders â€" A step towards mitochondria based therapeutic strategies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1066-1077.	4.2	1,360
144	A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. Biochemical and Biophysical Research Communications, 2017, 483, 1156-1165.	2.1	123

#	Article	IF	Citations
145	Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1078-1089.	4.2	522
146	Cell cycle activation in p21 dependent pathway: An alternative mechanism of organophosphate induced dopaminergic neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1858-1866.	4.2	16
147	Are microRNAs true sensors of ageing and cellular senescence?. Ageing Research Reviews, 2017, 35, 350-363.	12.1	90
148	Role of Glutamate and NMDA Receptors in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 1041-1048.	2.7	862
149	Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimerâ€™s disease. Human Molecular Genetics, 2017, 26, 1597-1597.	3.1	23
150	White Matter Deterioration May Foreshadow Impairment of Emotional Valence Determination in Early-Stage Dementia of the Alzheimer Type. Frontiers in Aging Neuroscience, 2017, 9, .	4.1	4
151	Lower Activation in Frontal Cortex and Posterior Cingulate Cortex Observed during Sex Determination Test in Early-Stage Dementia of the Alzheimer Type. Frontiers in Aging Neuroscience, 2017, 9, .	4.1	0
152	Impact of Exercise and Education in Adults of Lubbock, Texas: Implications for Better Lifestyle. Frontiers in Aging Neuroscience, 2016, 8, .	4.1	3
153	Stroke, Vascular Dementia, and Alzheimerâ€™s Disease: Molecular Links. Journal of Alzheimer's Disease, 2016, 54, 427-443.	2.7	253
154	Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimerâ€™s disease. Human Molecular Genetics, 2016, , ddw330.	3.1	141
155	Peripheral biomarkers of stroke: Focus on circulatory microRNAs. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1984-1993.	4.2	119
156	Protective Effects of a Natural Product, Curcumin, against Amyloid Î² Induced Mitochondrial and Synaptic Toxicities in Alzheimer'S Disease. Journal of Investigative Medicine, 2016, 64, 1220-1234.	1.7	150
157	Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimerâ€™s disease. Human Molecular Genetics, 2016, 25, 4881-4897.	3.1	166
158	Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1617-1627.	4.2	264
159	Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease. Human Molecular Genetics, 2016, 25, 1739-1753.	3.1	129
160	Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 814-828.	4.2	139
161	Garrison Institute on Aging: A New Hope forÂElderly Individuals and Patients withÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 547-555.	2.7	3
162	Garrison Institute on Agingâ€"Lubbock Retired and Senior Volunteer Program (RSVP) Provides Services to South Plains, Texas. Frontiers in Aging Neuroscience, 2015, 7, .	4.1	1

#	Article	IF	Citations
163	Mitochondrial division and fusion in metabolism. Current Opinion in Cell Biology, 2015, 33, 111-118.	4.2	197
164	Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. Human Molecular Genetics, 2015, 24, 7308-7325.	3.1	73
165	Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discovery Today, 2014, 19, 951-955.	7.7	100
166	Inhibitors of Mitochondrial Fission as a Therapeutic Strategy for Diseases with Oxidative Stress and Mitochondrial Dysfunction. Journal of Alzheimer's Disease, 2014, 40, 245-256.	2.7	144
167	Amyloid beta-induced glycogen synthase kinase 3Î² phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1913-1921.	4.2	137
168	Abnormal Interaction of Oligomeric Amyloid-Î² with Phosphorylated Tau: Implications to Synaptic Dysfunction and Neuronal Damage. Journal of Alzheimer's Disease, 2013, 36, 285-295.	2.7	79
169	Neurotransmitter CART as a New Therapeutic Candidate for Parkinsonâ€™s Disease. Pharmaceuticals, 2013, 6, 108-123.	4.4	19
170	MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2322-2331.	4.2	106
171	RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2368-2378.	4.2	40
172	Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 67-75.	4.2	74
173	Reduced VDAC1 Protects Against Alzheimer's Disease, Mitochondria, and Synaptic Deficiencies. Journal of Alzheimer's Disease, 2013, 37, 679-690.	2.7	68
174	Mitochondria-targeted catalase reduces abnormal APP processing, amyloid Â production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Human Molecular Genetics, 2012, 21, 2973-2990.	3.1	167
175	Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Human Molecular Genetics, 2012, 21, 406-420.	3.1	348
176	Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Human Molecular Genetics, 2012, 21, 2538-2547.	3.1	411
177	Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Human Molecular Genetics, 2012, 21, 5131-5146.	3.1	303
178	Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimerâ€™s Disease. Pharmaceuticals, 2012, 5, 1103-1119.	4.4	67
179	Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 639-649.	4.2	351
180	Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 101-110.	4.2	160

#	Article	IF	Citations
181	Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 862-874.	4.2	60
182	CART Peptide Is a Potential Endogenous Antioxidant and Preferentially Localized in Mitochondria. PLoS ONE, 2012, 7, e29343.	2.5	48
183	Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage. Journal of Cell Biology, 2012, 197, 535-551.	4.8	250
184	Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Human Molecular Genetics, 2011, 20, 4515-4529.	3.1	598
185	Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Research Reviews, 2011, 67, 103-118.	9.3	338
186	Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics. Pharmaceuticals, 2011, 4, 429-456.	4.4	126
187	Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 507-513.	4.2	218
188	Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1182-1189.	4.2	55
189	Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1359-1370.	4.2	278
190	A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics. Neuroscience Letters, 2011, 500, 212-215.	2.0	5
191	Toxicity of Neurons Treated with Herbicides and Neuroprotection by Mitochondria-Targeted Antioxidant SS31. International Journal of Environmental Research and Public Health, 2011, 8, 203-221.	3.1	36
192	Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Research, 2011, 1415, 136-148.	2.5	265
193	Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Human Molecular Genetics, 2011, 20, 1438-1455.	3.1	364
194	Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Human Molecular Genetics, 2011, 20, 2495-2509.	3.1	749
195	Amyloid-Î² and Mitochondria in Aging and Alzheimer's Disease: Implications for Synaptic Damage and Cognitive Decline. Journal of Alzheimer's Disease, 2010, 20, S499-S512.	2.7	229
196	Mitochondria-Targeted Antioxidants Protect Against Amyloid-Î² Toxicity in Alzheimer's Disease Neurons. Journal of Alzheimer's Disease, 2010, 20, S609-S631.	2.7	440
197	Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Human Molecular Genetics, 2009, 18, 3876-3893.	3.1	53
198	Mitochondrial structural and functional dynamics in Huntington's disease. Brain Research Reviews, 2009, 61, 33-48.	9.3	157

#	Article	IF	Citations
199	Granulocyteâ€macrophage colonyâ€stimulating factor antibody suppresses microglial activity: implications for antiâ€inflammatory effects in Alzheimerâ€™s Disease and multiple sclerosis. Journal of Neurochemistry, 2009, 111, 1514-1528.	4.0	28
200	Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Experimental Neurology, 2009, 218, 286-292.	4.2	253
201	Role of Mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease. CNS Spectrums, 2009, 14, 8-13.	0.7	175
202	Mitochondrial Medicine for Aging and Neurodegenerative Diseases. NeuroMolecular Medicine, 2008, 10, 291-315.	3.8	210
203	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine, 2008, 14, 45-53.	8.9	903
204	Mitochondrial Dysfunction in Aging and Alzheimer's Disease: Strategies to Protect Neurons. Antioxidants and Redox Signaling, 2007, 9, 1647-1658.	6.4	176
205	Mitochondria are a direct site of AÎ² accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 2006, 15, 1437-1449.	3.1	1,062
206	Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiology of Aging, 2006, 27, 1060-1077.	3.3	73
207	Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-13.	2.4	132
208	Neuronal protection by sirtuins in Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 305-313.	4.0	151
209	Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 1-13.	4.0	316
210	Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction. Journal of Alzheimer's Disease, 2005, 7, 103-117.	2.7	353
211	Interaction of the Nuclear Matrix Protein NAKAP With HypA and Huntingtin: Implications for Nuclear Toxicity in Huntington's Disease Pathogenesis. NeuroMolecular Medicine, 2005, 7, 297-310.	3.8	12
212	Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. Journal of Neurochemistry, 2005, 92, 494-504.	4.0	191
213	Can herbs provide a new generation of drugs for treating Alzheimer's disease?. Brain Research Reviews, 2005, 50, 361-376.	9.3	119
214	Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Research Reviews, 2005, 49, 618-632.	9.3	269
215	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Human Molecular Genetics, 2004, 13, 1225-1240.	3.1	325
216	Differential Expression of Oxidative Phosphorylation Genes in Patients With Alzheimer's Disease: Implications for Early Mitochondrial Dysfunction and Oxidative Damage. NeuroMolecular Medicine, 2004, 5, 147-162.	3.8	393

#	Article	IF	Citations
217	The use of real-time PCR analysis in a gene expression study of Alzheimerâ€™s disease post-mortem brains. Journal of Neuroscience Methods, 2004, 132, 101-107.	2.4	108
218	Huntingtonâ€™s Disease. American Journal of Human Genetics, 2004, 74, 781-782.	6.5	3
219	Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease. Journal of Neuroscience, 2001, 21, 9112-9123.	3.7	278
220	Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95. Journal of Biological Chemistry, 2001, 276, 24713-24718.	2.3	251
221	Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model. Neuroscience Letters, 2000, 283, 233-235.	2.0	95
222	Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genetics, 1998, 20, 198-202.	26.1	398